- Who We Are and What We Do
- Research Projects
- HIV Vaccine Trials Unit (HVTU)
- Penn Center for AIDS Research (CFAR)
- Risk Assessment Battery (RAB)
- Community Advisory Board
- Contact Us
- Support Our Work
- Follow Us on Twitter
Lisa A. Maslankowski, MD
Lisa A. Maslankowski, MD graduated from Temple University School of Medicine and completed her residency in Internal Medicine at University Hospitals of Cleveland, Case Western Reserve University and Medical College of Pennsylvania. Since joining the HIV Prevention Research Division of the Center for Studies of Addictions at the University of Pennsylvania in 1998, she has been the lead investigator for the Division’s HIV microbicide trials through the HIV Prevention Trials Network (HPTN) and the Microbicide Trials Network (MTN). Her research interests include microbicide clinical trials, HIV vaccine clinical trials, and adherence in microbicide trials. Dr. Maslankowski is also a recognized HIV clinical specialist and has served as the directing physician for two dedicated HIV clinics for the City of Philadelphia’s Department of Public Health from 1996 - 2004.
Mayer KH, Maslankowski L, Gai F, El-Sadr W, Justman J, Kwiecien A, Mâsse B, Eshleman SH7, Hendrix C, Morrow K, Rooney JF, Lydia Soto-Torres L, and the HPTN 050 Protocol Team. Safety and tolerability of Tenofovir vaginal gel in abstinent and sexually active HIV-uninfected and infected women. AIDS. 2006, 20:543-551.
El-Sadr W, Mayer KH, Maslankowski L, Hoesley, C, Justman J, Gai F, Mauck C, Absalon J, Morrow K, Mâsse B, et al. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS. 2006, 20:1109-1116.
Rosen, R, Morrow, K, Carballo-Dieguez, A, Mantell, J, Hoffman, S, Gai, F, Maslankowski, L, El-Sadr, W, Mayer, K. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed methods study. Journal of Women’s Health. 2008.
Carballo-Dieguez A, Balan, Morrow K, Rosen R, Mantell, Gai F, Hoffman S, Maslankowski L, El-Sadr W, Mayer K. Acceptability of tenofovir gel as a vaginal microbicide by U.S. male participants in a phase I clinical trial (HPTN 050). AIDS Care. 2007.
Joshi S, Dutta S, Bell B, Profy A, Kuruc J, Fang G, Cianciola M, Maslankowski L, Soto-Torres L, Panchanadikar A, Mehendale S, Reynolds SJ. Documenting intermenstrual bleeding in a vaginal microbicide study: case reports and lessons learned. AIDS Res Hum Retroviruses. 2006; 22:294-6.
Njoroge B, Chirenje ZM, Bina P, Florence M, Joshi S, Low-Beer N, Maslankowski L. The CONRAD/WHO Update 2000 Colposcopy Manual: how well is it working? J AIDS 2004, 35 (Supplement 2).
Mayer KH, Karim SA, Kelly C, Maslankowski L, Rees H, Profy AT, Day J, Welch J, Rosenberg Z for the HIV Prevention Trials Network (HPTN) 020 Protocol Team. Safety and tolerability of vaginal Pro 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 2003; 17:321-29.
Morrow, K, Rosen, R, Richter, L, Emans, A, Forbes, A, Day J, Morar, N, Maslankowski L, Profy AT, Cliff, K, Karim SA, Mayer KH. The acceptability of an investigational vaginal microbicide, PRO2000 Gel, among women in a Phase I clinical trial. Journal of Women’s Health, 2003, 12, 7:655-66.
Mayer KH, Kelly C, Morar NS, Maslankowski. L, Emans A, Welch J. The Safety and tolerability of PRO2000 Gel, a novel vaginal microbicide, in sexually active HIV- and abstinent HIV+ women (HIVNET020). Int J STDs & AIDS 2001; 12 (suppl 2):35.
Back to Top